Ginkgo Bioworks
DNA
315 hedge funds and large institutions have $2.25B invested in Ginkgo Bioworks in 2023 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 121 increasing their positions, 62 reducing their positions, and 41 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 62
49% more capital invested
Capital invested by funds: $1.51B → $2.25B (+$736M)
5% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 41
1% more funds holding
Funds holding: 313 → 315 (+2)
0.1% more ownership
Funds ownership: 1.81% → 1.91% (+0.1%)
23% less call options, than puts
Call options by funds: $5.42M | Put options by funds: $7.03M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.8M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$12.1M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$12.1M |
| 5 |
Millennium Management
New York
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.2M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.5M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$3.47M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$3.25M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$2.65M |
DNA Hedge Fund Activity: Q2 2023 in Review
315 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q2 2023, worth a combined $2.25B — up 49% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new DNA positions and 41 closed out — a net gain of 2 holders — while 121 added to existing stakes and 62 trimmed.
The largest buyer was BlackRock, adding an estimated $26M. The largest seller was Morgan Stanley, cutting an estimated $16.2M.
- 315 institutional investors held Ginkgo Bioworks (DNA) as of Q2 2023, up from 313 in Q1 2023.
- Funds reported $2.25B of Ginkgo Bioworks stock for Q2 2023, up 49% quarter-over-quarter.
- 43 funds opened new Ginkgo Bioworks positions in Q2 2023 and 41 closed out, a net change of +2 holders.
- The largest Ginkgo Bioworks buyer in Q2 2023 was BlackRock, an estimated $26M added.
- The largest Ginkgo Bioworks seller in Q2 2023 was Morgan Stanley, an estimated $16.2M sold.
Based on aggregated 13F filings for Q2 2023.